MoonLake Immunotherapeutics
MLTX
$16.77
$0.040.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -14.70% | -1.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.70% | 17.69% | |||
| Operating Income | 8.70% | -17.69% | |||
| Income Before Tax | 11.06% | -26.13% | |||
| Income Tax Expenses | 115.65% | 21.05% | |||
| Earnings from Continuing Operations | 10.86% | -26.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -38.76% | 16.13% | |||
| Net Income | 10.47% | -26.27% | |||
| EBIT | 8.70% | -17.69% | |||
| EBITDA | 8.80% | -17.90% | |||
| EPS Basic | 16.52% | -26.09% | |||
| Normalized Basic EPS | 16.51% | -26.21% | |||
| EPS Diluted | 16.52% | -26.09% | |||
| Normalized Diluted EPS | 16.51% | -26.21% | |||
| Average Basic Shares Outstanding | 7.26% | 0.14% | |||
| Average Diluted Shares Outstanding | 7.26% | 0.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||